Background: Brimonidine is an a 2 -adrenergic agonist that decreases aqueous humour production and may increase uveoscleral outflow. It has not been evaluated in normal or glaucomatous equine eyes. Objectives: To evaluate the efficacy and safety of brimonidine in lowering intraocular pressure (IOP), alone and in conjunction with timolol, as a treatment for equine glaucoma by comparing IOP in normal equine eyes treated with brimonidine and brimonidine-timolol, respectively, with IOP in control eyes. Study design: A balanced crossover design with 16 horses receiving one of two treatments, brimonidine and brimonidine-timolol, during each of two 10-day study phases, was used. Four horses were randomly assigned to each of four combinations of treated eye (right or left) and drug order within the two 10-day study phases (brimonidine first or brimonidine-timolol first). Methods: Pupil size and conjunctival hyperaemia were assessed twice per day and IOP was measured three times per day using rebound tonometry in both eyes of 16 normal horses throughout two 10-day study periods (brimonidine and brimonidine-timolol) separated by an 18-day washout period. One eye of each horse was treated with brimonidine or brimonidine-timolol and the opposite eye was treated with balanced salt solution (BSS). Results: There were no adverse effects and no significant changes in pupil size in normal equine eyes treated with brimonidine or brimonidine-timolol. Average IOP in normal equine eyes treated with brimonidine (25.6 mmHg) was statistically higher than in eyes treated with brimonidine-timolol (24.6 mmHg) or BSS (24.5 mmHg). However, IOP differences were of ≤1 mmHg and thus not clinically important. Main limitations: Horses with normal eyes may not be as sensitive to the IOP-lowering effects of treatment as horses with glaucoma. Conclusions: Brimonidine and brimonidine-timolol are well tolerated in normal horses but do not decrease IOP.
Introduction
Glaucoma is a devastating disease associated with irreversible degeneration of the optic nerve, which may lead to blindness in horses. Although the specific mechanisms contributing to the initiation and progression of most cases of glaucoma are unknown, the primary risk factor is increased intraocular pressure (IOP). Increased IOP is caused by an imbalance in the production and outflow of aqueous humour. In horses, elevated IOP usually occurs in response to decreased outflow of aqueous humour, which is usually secondary to uveitis [1] [2] [3] . In eyes with uveitis, there is an infiltration of inflammatory cells and damage to the trabecular meshwork, which makes it more difficult for aqueous humour to exit the eye.
Only a few topical ophthalmic medications have proven to be effective in decreasing IOP, and therefore presumptively in managing glaucoma, in horses. All of these compounds lower IOP by reducing aqueous humour production and include the carbonic anhydrase inhibitors dorzolamide, and brinzolamide, and the b-blocker timolol [1] [2] [3] . Brinzolamide was found to lower IOP by an average of 14-21% in normal horses, depending on whether it was administered once or twice per day [1] . Dorzolamidetimolol was found to lower IOP by an average of 13% when measured in clinically normal horses [4] . Timolol decreased IOP by an average of 17% in clinically normal horses [5] . These are relatively small changes in IOP and, in the present authors' experience, these medications are not effective in all horses with glaucoma. In addition, several glaucoma medications, including latanoprost and pilocarpine, that are effective in human or canine patients are either ineffective or irritating in horses [6] [7] [8] . Thus, there is a need for more effective therapeutic options for glaucoma in horses.
Brimonidine is a commercially available a 2 -adrenergic receptor agonist that is approved by the US Food and Drug Administration for the treatment of glaucoma in human subjects [9] . The a 2 -adrenergic receptor agonists decrease IOP by inhibiting adenylate cyclase causing decreased cAMP, which is necessary for the production of aqueous humour. Xylazine, a systemic a 2 -adrenergic receptor, has been shown to reduce IOP by 20% in horses [10] . In addition to decreasing production, brimonidine may increase aqueous humour outflow via the uveoscleral pathway in which fluid exits the eye by diffusing through the ciliary body and sclera [9] [10] [11] . Horses are unique in that they rely more heavily on uveoscleral outflow than do most species [2, 3] . Therefore, brimonidine may decrease IOP by several different mechanisms in horses.
Timolol is a b-adrenergic receptor antagonist that reduces production of aqueous humour and is effective in decreasing IOP in normal horses [10] . Brimonidine and timolol administered separately to human patients with glaucoma have been demonstrated to reduce IOP by very similar amounts [12] ; however, fixed combinations of brimonidine and timolol have been shown to decrease IOP further than either drug administered alone [9, 11, 13] . In addition, trials in human patients with glaucoma demonstrated that brimonidine alone caused more adverse reactions than timolol alone. However, the combining of medications reduced adverse reactions to an incidence lower than that associated with brimonidine alone [11] . Thus, the present group is interested in investigating the effects of both brimonidine and a fixed combination of brimonidine and timolol on IOP in normal horses. Therefore, the objectives of this study were to evaluate the IOPlowering efficacy and safety of brimonidine, alone and in conjunction with timolol, in normal equine eyes.
Materials and methods

Animals
Sixteen horses (10 geldings and six mares) with a median age of 11.5 years (range: 8-18 years) were used in this study. Horses included 13 Thoroughbreds, two Warmbloods and one Quarter Horse. Prior to initiation of the study, each horse underwent a thorough ophthalmic examination performed by one of two board-certified veterinary ophthalmologists and was confirmed to be free of ocular disease. Specifically, hand-held slit lamp biomicroscopy (SL-15 a ) and indirect ophthalmoscopy with a 2.2-D lens b and a binocular indirect ophthalmoscope c were performed. Each horse was housed in a covered pen during the study periods and in a paddock during recovery periods. All horses received their usual diet throughout the study periods.
Study design and medication administration
This study was approved by the University of California Davis Institutional Animal Care and Use Committee and performed according to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Visual Research. Sixteen horses were used in a balanced crossover design; eight horses each received each of the two treatments (0.2 mL of 0.2% brimonidine tartrate ophthalmic solution or 0.2% brimonidine tartrate-0.5% timolol maleate ophthalmic solution) during either phase 1 or phase 2. A 1-mL syringe with a 250-G, ¾-inch needle was filled with either the medication or placebo (balanced salt solution [BSS] ). The needle was broken off the hub and the medication was squirted into the eye [12] . Horses were randomly assigned to treatment order, such that each horse received one of the two treatments, either brimonidine or brimonidine-timolol, in one randomly selected eye and 0.2 mL of BSS in the opposite eye every 12 h (at 07.00 and 19.00 h) for 5 days during phase 1 and then, after an 18-day washout period, received the other treatment every 12 h for 5 days during phase 2. Each study period comprised 10 days, during which baseline measurements were obtained on days 1-3, measurements were continued and treatment was given on days 4-8, and measurements were continued post-treatment on days 9 and 10. Fourteen horses completed both treatment trials and two horses completed only a single trial because they were removed from the study at the conclusion of phase 1 after they became refractory to the administration of medications and performance of IOP measurements. One of these horses had completed phase 1 in the brimonidine treatment group, and the other horse had completed phase 1 in the brimonidinetimolol treatment group.
Acclimation and measurement of IOP, pupil size and conjunctival hyperaemia
Four days prior to the beginning of study phase 1, horses were moved into the pens in which the trial was conducted in order to begin the acclimation period. During the acclimation period, a single evaluator measured IOP using rebound tonometry (Icare Tono Vet d ) in each horse twice per day to acclimate the horses to the procedure. Positive reinforcement with horse treats (Manna Pro Bite Size Nuggets e ) was used to train the horses to stand calmly for the duration of IOP measurement. IOP was measured until consistent readings were achieved in each horse and horses were no longer reactive to measurement. All of the horses acclimated well over the 4-day period and the authors were able to use positive reinforcement to obtain accurate measurements without need for sedation or topical anaesthesia.
During the study period, IOP was measured by the same single evaluator masked to treatment three times per day (07.00, 13.00 and 19.00 h). The measurements were taken with the horse standing calmly in a shaded portion of the covered pen with the head maintained in an appropriate position (i.e. not below the heart) [13] . No topical anaesthetics, systemic sedatives or local nerve blocks were used to obtain measurements. At each timepoint, three IOP readings were recorded. As per the Icare TonoVet d manual, each IOP reading represents an average calculated by the rebound tonometer of four of six IOP measurements, with the highest and lowest measurements of the six excluded. The IOP reading also includes a categorical measure of variability, with 'no bar' readings having an s.d. of <1.0 mmHg, 'low bar' readings having an s.d. of 1.8-2.5 mmHg, 'medium bar' readings having an s.d. of 2.5-3.5 mmHg, and 'high bar' readings having an s.d. of >3.5 mmHg. At each timepoint, IOP measurements were continued until three IOP readings classified by the tonometer as having no bar, a low bar or a medium bar had been obtained. These three IOP readings were recorded; no IOP readings with a high bar were included in the set of three readings recorded at each timepoint. Vertical pupil size was measured in millimetres using a standard 30-cm/12-inch ruler held up to the horse's eye in line with the pupil. Conjunctival hyperaemia was graded by the same single observer twice per day (at 07.00 and 19.00 h) in each eye of each horse during each 10-day study period using a previously published semiquantitative scale. Briefly, conjunctival hyperaemia was subjectively assessed using a scale of 0-3, on which 0 = none, 1 = mild, 2 = moderate and 3 = severe conjunctival hyperaemia.
Although systemic a 2 -adrenergic receptor agonists such as xylazine and detomidine are commonly administered in horses for sedative purposes and are typically well tolerated, horses participating in this study were closely monitored for signs of adverse reactions to topical ophthalmic brimonidine and a fixed combination of brimonidine and timolol.
Data analysis
Mixed-effects linear regression was used to evaluate the main effects of and interactions between treatment (control, brimonidine or brimonidine-timolol), eye (right or left), time (07.00, 13.00 and 19.00 h) and, when appropriate, age, breed and sex of the horse for IOP and pupil size. Treatment order (brimonidine in phase 1 and brimonidinetimolol in phase 2, or vice versa) was controlled but not analysed. The individual horse was treated as a random effect; all other variables were considered as fixed effects. For IOP measurements, data were analysed in three ways: 1) as the average of all three readings recorded at each timepoint (i.e. including those with no bar, low bar and medium bar); 2) as individual replicates, and 3) as individual replicates with medium bar readings excluded. These three methods of data analysis were performed to investigate the robustness of any observed effect across analysis methods in order to help determine if one method was more sensitive than the others. Analyses were performed using Stata/IC Version 12.1.
f All measurements were expressed as the mean AE s.d. For all analyses, P values of ≤0.05 were considered to indicate statistical significance.
Results
All horses tolerated topical administration of brimonidine, brimonidinetimolol or BSS with no evidence of ocular discomfort or conjunctival hyperaemia at any time during the study. Using mixed-effects linear regression modelling, treatment, eye, time of day, sex and age effects on IOP were determined at baseline and during the entire measurement period.
Treatment effects on IOP
There was no difference in statistical outcomes between groups when data were analysed in three different ways (i.e. as the average of the three recorded measurements, as individual replicates, or as individual replicates with medium bar readings excluded). Thus, only the IOP averaged data will be shown and discussed. Although IOP estimated from measurements taken during baseline, BSS control, brimonidine treatment, brimonidinetimolol treatment and recovery conditions were all within approximately 1 mmHg, there was a statistical difference (P = 0.001) in IOP following treatment with brimonidine (predicted mean: 25. (Fig 1) .
Eye, time of day, sex and age effects on IOP 2), respectively (P = 0.038). At baseline, IOP was significantly greater at 13.00 h than at 07.00 and 19.00 h at 25.8 mmHg (95% CI 24.5-27.1), 24.1 mmHg (95% CI 22.8-25.5) and 24.2 mmHg (95% CI 22.8-25.5), respectively (P<0.05) (Fig 1) . Age did not significantly alter IOP at baseline (P = 0.964) or within the entire measurement period (P = 0.883).
Pupil size
Using mixed-effects linear regression modelling, overall treatment effects on vertical pupil size were determined. Treatment with brimonidine, brimonidine-timolol or BSS did not have a significant effect (P>0.05) on pupil size in comparison with that at baseline (Fig 2) . However, predicted mean vertical pupil size was significantly greater (P<0.001) during the recovery period (6.6 mm, 95% CI 6.0-7.1) in comparison with baseline (5.7 mm, 95% CI 5.2-6.2), and treatment with brimonidine (5.7 mm, 95% CI 5.2-6.3), brimonidine-timolol (5.8 mm, 95% CI 5.3-6.4) or BSS (5.9 mm, 95% CI 5.4-6.5) (Fig 2) . Predicted mean vertical pupil size was significantly greater (P<0.001) at 07.00 h (7.3 mm, 95% CI 6.7-7.8) than at 19.00 h (4.6 mm, 95% CI 4.1-5.2).
Discussion
This study was designed to evaluate brimonidine and brimonidine-timolol as treatments for equine glaucoma. Specifically, the objective was to evaluate the IOP-lowering efficacy and safety of brimonidine, alone and in conjunction with timolol, as a potential treatment for equine glaucoma by comparing IOP in normal equine eyes treated with brimonidine or brimonidine-timolol with that in control eyes. Brimonidine was found to statistically significantly increase IOP in comparison with values obtained at baseline, and during treatment with BSS and brimonidine-timolol, although these differences were of no clinical importance. By contrast, brimonidinetimolol did not significantly change IOP in comparison with baseline or BSS. No ocular irritation was identified in any of the horses and neither brimonidine nor brimonidine-timolol significantly affected pupil size.
Brimonidine did not seem to cause any negative side effects in normal horses as no horse displayed any conjunctival hyperaemia or other noticeable ocular problem during the 5-day treatment period. This observation suggests that it may be safe to use brimonidine in horses with glaucoma; however, brimonidine was administered for only 5 days and hence the possible long-term side effects were not evaluated. Studies in human subjects have reported that brimonidine can cause stinging [13] , but it is difficult to determine whether the feeling of stinging is a factor in horses. However, no horses showed any blepharospasm or other signs of ocular pain during the treatment period. .00 h) prior to, during and following administration at 07.00 and 19.00 h of topical ophthalmic a) 0.2% brimonidine or b) 0.2% brimonidine tartrate and 0.5% timolol maleate combination in one eye and balanced salt solution (BSS) in the opposite eye every 12 h in 15 horses. A balanced crossover design was used in which eight horses received brimonidine and eight horses received brimonidine-timolol. After an 18-day washout period, the alternative treatment was administered. Predicted mean IOP following treatment with brimonidine was significantly greater (P = 0.001) than baseline values, control measurements with BSS and recovery values. However, there was no significant difference (P>0.05) between values obtained with brimonidine-timolol, baseline values, control measurements with BSS and recovery values. IOP was significantly greater (P<0.05) at 13.00 h than at 07.00 and 19.00 h.
Of the two horses that became refractory to treatment and thus were removed from the study after the first study period, one was receiving brimonidine alone and the other was receiving brimonidinetimolol, which is reported to have fewer side effects in human subjects than brimonidine alone [9] . It is more likely that these two horses became refractory to IOP measurement and treatment as a result of either the intense handling of horses with only a short break between IOP measurements or the administration of topical ophthalmic medications twice per day. The medications were administered using a syringe capped with a needle broken off at the hub so that the ophthalmic solutions could be gently sprayed into the horses' eyes. This method of administration may have been irritating to the horses and resulted in their becoming refractory to treatment, although any effect on IOP of refractory behaviour should have affected all treatment conditions equally. It is actually impressive that 14 of 16 horses were able to complete both treatment phases of the study without sedation, or the need for topical corneal anaesthetic or local nerve block to facilitate manual opening of the eyelids; this perhaps testifies to the importance of acclimation to the study environment in general and to IOP measurement in particular in studies of IOP in horses.
Although there was a statistically significant increase in IOP associated with brimonidine treatment, it was of <1 mmHg. The detection of such a small magnitude of effect is likely to be associated both with the fact that animals were generally well acclimated to the procedure and with the collection of a very large number of measurements as over 1800 IOP measurements were collected throughout the study. Furthermore, a 1-mmHg difference does not represent a clinically significant increase in IOP. It is possible that this was a real effect and that brimonidine was ineffective in lowering IOP in normal horses. Timolol is generally believed to cause modest reductions in IOP in normal horses but it was ineffective in combination with brimonidine, possibly because of a counter effect of brimonidine or because this set of horses was non-responsive to either drug. In a study of beagles with glaucoma, brimonidine showed a trend in, but was not statistically significant at, lowering IOP [14] . This suggests that some dogs responded to brimonidine with a reduction in IOP, but most did not.
An important concept to recognise is that not every human or animal subject responds with a reduction in IOP even when the drug is generally regarded as highly effective in causing a mean reduction in IOP in the general population [15] [16] [17] [18] . For example, up to 15% of human subjects do not respond to some of the most effective topical prostaglandin analogues [15] [16] [17] [18] . Studies in normal cats with prostaglandin analogues that are highly effective in human subjects suggest that the non-responder rate may approach 100% [19] . Similarly, although timolol has been reported to reduce IOP in dogs by 16.1% [20] , in a more recent study of the effects of latanoprost, timolol and a latanoprost-timolol combination on pupil size, IOP and heart rate in nine normal dogs, there was no decrease in IOP in 11% of the dogs when treated with latanoprost alone, and there was no decrease in IOP in any of the nine dogs when treated with timolol alone [21] . Therefore, it is possible that the individuals in this population of horses were not responsive to timolol, whereas in the previous study [4, 5] the number of horses responsive was sufficient to lower mean IOP by a statistically significant amount.
Eye, time of day, sex and age were evaluated for potential effects on IOP. The small but statistically greater IOP in the left vs. the right eye may be associated with laterality of handling as most horses are used to being handled on their left, or near, side. There is some evidence that horses prefer to use their left eye for assessment and evaluation [22] and therefore perhaps horses in this study exhibited a squinting artefact that affected IOP measurement in the left eye more than in the right. IOP was greatest at midday, which is consistent with previously reported circadian IOP rhythmicity in horses showing the highest IOP during peak light [23] . There was no age effect during the entire measurement period, and no sex effect on IOP at baseline; however, mares exhibited a 2-mmHg greater IOP than geldings during the treatment phase. The reason for this is unknown.
Horses included in the study were fed at different times each morning. Feeding sometimes interrupted IOP measurement and treatment administration. In addition, because the horses were in open pens, they were able to observe the movement of other horses around the farm. Excitement associated with feeding and with the movement of other horses may have affected measured IOP; however, the statistically significant and consistent diurnal change in IOP indicates that the data reflect normal physiological occurrences in relation to IOP, and also suggests that the measurements were not altered sporadically by fluctuations in the amounts of stress experienced by the horses.
There were no significant effects of brimonidine or brimonidinetimolol on vertical pupil size in this study. However, as expected, vertical pupil size varied throughout the day, was largest in the morning and significantly decreased in the afternoon and early evening. This is most likely associated with changes in ambient lighting caused by differential shading based on the height of the sun (i.e. the pens housing the horses were most shaded when the sun was directly overhead in the middle of the day).
Although treatments containing brimonidine did not lower IOP in normal horses, it is possible that horses with glaucoma will show an IOP-lowering effect. Whereas brimonidine has been shown to be effective at decreasing IOP in human subjects with glaucoma [10, 11] , it was ineffective at significantly decreasing IOP in beagles with glaucoma [14] . Changes in IOP in normal animals can be subtle and the results are usually magnified in animals with glaucoma [24] [25] [26] . Thus, it would be ideal to conduct a clinical trial in horses with glaucoma to establish whether brimonidine or brimonidine-timolol can decrease IOP in equine patients.
In conclusion, this study showed brimonidine and brimonidine-timolol were safe to use in normal horses, with no adverse systemic or ocular effects noted. However, the efficacy of these treatments in horses with glaucoma is questionable because although brimonidine statistically significantly increased IOP in normal horses, this increase amounted to <1 mmHg and is considered clinically insignificant. It is unknown whether horses with glaucoma will achieve some IOP-lowering benefit from the use of brimonidine with or without timolol; further studies using clinical patients are warranted.
interpretation. All authors contributed to the preparation of the paper and approved the final manuscript. 
Manufacturers' addresses
